[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363719-105":59,"doc-detail-363719-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","discovery-of-macrocyclic-peptide-inhibitors-targeting-myc-oncoprotein-via-mrna-display","Discovery of Macrocyclic Peptide Inhibitors Targeting MYC Oncoprotein via mRNA Display","","mRNA display technology enables discovery of macrocyclic peptides against difficult proteins, yet direct screening for the “undruggable” transcription factor MYC has been limited. This study integrates tyrosinase-mediated cyclization with mRNA display to identify macrocyclic peptide inhibitors targeting MYC, then evaluates antiproliferative effects in MYC-dependent tumor cells by CCK-8. TAT-derived cell-penetrating peptide fusions enhance membrane uptake, while binding is quantified by BLI and MYC pathway suppression is measured using RNA-seq of canonical MYC targets.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/discovery-of-macrocyclic-peptide-inhibitors-targeting-myc-oncoprotein-via-mrna-display/363719/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/discovery-of-macrocyclic-peptide-inhibitors-targeting-myc-oncoprotein-via-mrna-display/363719.png","ImageObject",300,407,{"name":92,"@type":93},"Bulrr","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-11","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",18,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What challenge does this study address regarding MYC targeting?","Question",{"text":113,"@type":114},"Direct inhibition of MYC is difficult because it is considered “undruggable” due to intrinsic disorder and the lack of well-defined binding pockets. The study targets MYC using mRNA display to discover macrocyclic peptide inhibitors.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were macrocyclic peptide inhibitors generated and optimized for cell entry?",{"text":118,"@type":114},"Macrocyclic peptides were generated using mRNA display combined with tyrosinase-mediated cyclization. To improve cellular permeability, the peptides were fused to a TAT-derived cell-penetrating peptide at the C-terminus.",{"name":120,"@type":111,"acceptedAnswer":121},"How did the researchers confirm MYC binding and functional suppression?",{"text":122,"@type":114},"Binding affinities were measured by bio-layer interferometry (BLI), showing dose-dependent binding and micromolar Kd values. RNA-seq analysis demonstrated downregulation of canonical MYC target genes after treatment with a lead TAT-fusion peptide.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},363719,1790197970,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},5909892115043,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Article  \nDiscovery of Macrocyclic Peptide Inhibitors Targeting MYCOncoprotein via mRNA Display  \nJinzhu Chen 1, Fanglin Li 2, Chenguang Yuan 2, Xiaoling Geng 3, Yu Zhang 3, Qiurong Ding 1 and Yan Chen 1,2,3, *  \nAcademic Editor: Paweł Kafarski  \nReceived: 21 March 2026  \nRevised: 28 April 2026  \nAccepted: 6 May 2026  \nPublished: 22 June 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China; [chenjinzhu2022@sinh.ac.cn](chenjinzhu2022@sinh.ac.cn) (J.C.)  \n2 Shenzhen Sungening Biological Co., Ltd., Shenzhen 518172, China  \n3 School of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China  \n* [Correspondence: ychen3@sibs.ac.cn](Correspondence: ychen3@sibs.ac.cn)  \nAbstract  \nBackground/Objectives: mRNA display technology has emerged as a powerful platform for discovering macrocyclic peptides against intractable proteins. However, direct screening against the “undruggable” transcription factor MYC using this approach remains largely unexplored. In this study, we aimed to integrate tyrosinase-mediated cyclization with mRNA display to identify novel macrocyclic peptide inhibitors targeting MYC. Methods: We performed mRNA display combined with tyrosinase-mediated cyclization to generate macrocyclic peptides targeting MYC. Antiproliferative activity was assessed in MYCdependent tumor cells using CCK8 assay. C-terminal fusions with a TAT-derived cellpenetrating peptide were generated to enhance cell membrane permeability. Binding affinities were measured by bio-layer interferometry (BLI). MYC transcriptional activity was evaluated by RNA sequencing (RNA-seq) analysis of canonical MYC target genes. Results: The identified macrocyclic peptides exhibited potent antiproliferative activity against MYC-dependent tumor cells, with half-maximal inhibitory concentration (IC 50) values in the micromolar range. Fusion with the TAT peptide improved antiproliferative potency, yielding IC 50 values of 1–3 µM in MYC-dependent cell lines. BLI assays confirmed dose-dependent binding of the peptides to MYC, with dissociation constants (Kd) in the micromolar range. Furthermore, RNA-seq analysis revealed significant downregulation of canonical MYC target genes upon treatment with the TAT-fusion macrocyclic peptide, indicating specific suppression of MYC transcriptional activity. Conclusions: This work establishes the feasibility of using mRNA display to target the “undruggable” protein MYCand identifies a panel of macrocyclic peptides as promising lead candidates for further optimization toward targeted therapies for MYC-driven cancers.  \nKeywords: mRNA display; MYC; macrocyclic peptide; tumor treatment; undruggable target  \n1. Introduction  \nMYC is one of the most frequently dysregulated oncogenes in human cancers [1,2] . However, its intrinsic disorder and lack of well-defined binding pockets have long made it“undruggable” [2–5] . Multiple therapeutic strategies targeting MYC have been explored, but each has inherent limitations [4,6–8] . For instance, small-molecule inhibitors like 10058-F4 and 10074-G5 [9,10], identified through high-throughput screening, suffer from low affinity, poor cellular permeability, and limited selectivity. Similarly, the miniprotein  \nOmomyc (OMO-103) [11] has its own drawbacks including limited cell-penetrating ability, the need for high concentrations to exhibit activity, and susceptibility to proteolytic degradation. In addition, PROTAC-based degraders such as WBC100 face challenges in aspects like delivery efficiency, potential resistance, and complex pharmacokinetics [12,13] . These limitations highlight the urgent need for novel therapeutic approaches integrati","cbCail8oEGerIrJn","https://ap.wps.com/l/cbCail8oEGerIrJn","pdf",2621008,14,"English","# Abstract\n# 1. Introduction\n# 2. Results\n## 2.1. mRNA Display Selection of Macrocyclic Peptides Targeting MYC","[{\"question\":\"What challenge does this study address regarding MYC targeting?\",\"answer\":\"Direct inhibition of MYC is difficult because it is considered “undruggable” due to intrinsic disorder and the lack of well-defined binding pockets. The study targets MYC using mRNA display to discover macrocyclic peptide inhibitors.\"},{\"question\":\"How were macrocyclic peptide inhibitors generated and optimized for cell entry?\",\"answer\":\"Macrocyclic peptides were generated using mRNA display combined with tyrosinase-mediated cyclization. To improve cellular permeability, the peptides were fused to a TAT-derived cell-penetrating peptide at the C-terminus.\"},{\"question\":\"How did the researchers confirm MYC binding and functional suppression?\",\"answer\":\"Binding affinities were measured by bio-layer interferometry (BLI), showing dose-dependent binding and micromolar Kd values. RNA-seq analysis demonstrated downregulation of canonical MYC target genes after treatment with a lead TAT-fusion peptide.\"}]","Discovery of Macrocyclic Peptide Inhibitors Targeting MYC Oncoprotein via mRNA Display | PDF",1790152837,35,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6d7428925373a9e34c9bc240ded4d2b6.webp",983,1390,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/58b2948a19bb9e0cffeb8edc2329848c.webp",982,1388,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/eba77f24680080c5da933a5e19d24fb9.webp",981,1387,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/38e22a9683479a681170d7c6f83826d8.webp",980,1385]